Eli Lilly, Amgen tout U.S. investments amid Trump tariffs

Core Insights - President Donald Trump imposed 100% tariffs on pharmaceuticals, with exemptions for companies that build manufacturing plants in the U.S. [2] - Eli Lilly and Amgen announced new investments in the U.S. shortly after the tariff announcement [2] Company Actions - Eli Lilly is opening a new manufacturing facility in the U.S. as part of its investment strategy [2] - Amgen is also making significant investments in domestic manufacturing in response to the tariff policy [2]